iCo Therapeutics (iCo Therapeutics) Total Liabilities : $1.53 Mil (As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Total Liabilities?

iCo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2021 was $1.53 Mil.

iCo Therapeutics's quarterly Total Liabilities increased from Sep. 2020 ($0.83 Mil) to Dec. 2020 ($1.01 Mil) and increased from Dec. 2020 ($1.01 Mil) to Mar. 2021 ($1.53 Mil).

iCo Therapeutics's annual Total Liabilities increased from Dec. 2018 ($0.60 Mil) to Dec. 2019 ($0.61 Mil) and increased from Dec. 2019 ($0.61 Mil) to Dec. 2020 ($1.01 Mil).

iCo Therapeutics Total Liabilities Historical Data

The historical data trend for iCo Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Total Liabilities Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Liabilities

Get a 7-Day Free Trial

0.10

0.23

0.60

0.61

1.01

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Liabilities	Get a 7-Day Free Trial															0.82	0.83	0.83	1.01	1.53

iCo Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

iCo Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.013	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.01

Total Liabilities	=	Total Assets (A: Dec. 2020 )	-	Total Equity (A: Dec. 2020 )
	=	0.426	-	-0.586
	=	1.01

iCo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.528	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.53

Total Liabilities	=	Total Assets (Q: Mar. 2021 )	-	Total Equity (Q: Mar. 2021 )
	=	1.738	-	0.21
	=	1.53

iCo Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines